跳转至内容
Merck
CN

11099

氧化砷(III)

puriss. p.a., ACS reagent, 99.95-100.05% (RT)

别名:

三氧化二砷, 亚砷酸

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
As2O3
化学文摘社编号:
1327-53-3
分子量:
197.84
UNSPSC Code:
12352300
PubChem Substance ID:
57646847
EC Number:
215-481-4
MDL number:
MFCD00003433

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI key

IKWTVSLWAPBBKU-UHFFFAOYSA-N

InChI

1S/As2O3/c3-1-5-2-4

SMILES string

O=[As]O[As]=O

grade

ACS reagent, puriss. p.a.

vapor pressure

0.000001 mmHg ( 66 °C)

assay

99.95-100.05% (RT)

form

powder

anion traces

chloride (Cl-): ≤0.005%, sulfide (S2-): Pass

cation traces

Fe: ≤5 ppm, Pb: ≤0.002%, Sb: ≤0.05%

正在寻找类似产品? 访问 产品对比指南

Other Notes

A -D suffix exists for administrative purposes only.
All -D packages are 100% the same product, same quality, same specification as the package sizes previously sold without a -D.

signalword

Danger

Hazard Classifications

Acute Tox. 2 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1A - Eye Dam. 1 - Skin Corr. 1B - STOT RE 1

target_organs

Respiratory system,Cardio-vascular system,Gastrointestinal tract

存储类别

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
SLBD0655V
SLBC9730V
SLBB6616V
SLBB0811V
BCBC3502V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Xinquan Li et al.
Cancer investigation, 22(3), 389-400 (2004-10-21)
Arsenic trioxide is valuable for treatment of promyelocytic leukemia, but less attention has been paid to its therapeutic potential for other cancers. In this study, the effects of arsenic trioxide were tested in human pancreatic (AsPC-1), colonic (HT-29), and breast
Z X Shen et al.
Blood, 89(9), 3354-3360 (1997-05-01)
The therapeutic effect of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL) was evaluated among 15 APL patients at relapse after all-trans retinoic acid (ATRA) induced and chemotherapy maintained complete remission (CR). As2O3 was administered intravenously at
Huihui Wang et al.
Environmental toxicology, 28(5), 267-275 (2013-04-17)
Although arsenic is effective in the treatment of acute promyelocytic leukemia (APL), as a well-known environmental toxicant, the side effects of arsenic treatment and arsenic methylation metabolism of the patients are rarely reported. In this manuscript, we investigated 23 APL
Angela M Mitchell et al.
Journal of virology, 87(8), 4571-4583 (2013-02-15)
Interactions with cellular stress pathways are central to the life cycle of many latent viruses. Here, we utilize adeno-associated virus (AAV) as a model to study these interactions, as previous studies have demonstrated that cellular stressors frequently increase transduction of
Lauren A Held et al.
Cancer investigation, 31(3), 172-176 (2013-02-15)
This Phase I study assessed the feasibility of concomitant arsenic trioxide (ATO), ascorbic acid (AA), and bortezomib (Velcade™) (AAV) for patients with relapsed/refractory multiple myeloma. ATO (0.25 mg/kg) and AA (1 g) were given with an escalating dose of bortezomib
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持